Key Takeaways
- • California Governor Gavin Newsom signed Assembly Bill 1415 (AB 1415) and Senate Bill 351 (SB 351) into law on October 11, 2025, establishing the most comprehensive state-level regulatory framework for private equity and hedge fund activity in healthcare, effective January 1, 2026.
- • AB 1415 expands the Office of Health Care Affordability (OHCA) jurisdiction to require private equity groups, hedge funds, management services organizations (MSOs), and entities controlling healthcare providers to submit transaction notices and submit to regulatory review of ownership/control changes, mergers, and acquisitions.
- • SB 351 establishes explicit enforcement mechanisms authorizing California's attorney general to pursue legal action against private equity groups and hedge funds that interfere with independent clinical decision-making by physicians and dentists, largely codifying existing case law into statutory authority.
- • The legislation signals California's intensified scrutiny of healthcare consolidation and reflects multi-year state efforts to limit financial entity influence on healthcare markets, requiring stakeholders to account for extended review timelines in deal structuring.
- • OHCA gains authority to collect and analyze data from covered financial entities regarding their impact on healthcare costs, quality, access, and market competition, establishing a precedent for transparency in alternative investment participation in healthcare.
Summary
California has enacted sweeping legislation to regulate private equity and hedge fund involvement in healthcare, marking a significant shift toward state-level oversight of alternative asset managers' healthcare investments. Assembly Bill 1415 and Senate Bill 351, both signed by Governor Gavin Newsom on October 11, 2025, create a dual regulatory framework designed to address concerns about consolidation, cost impacts, and clinical independence in the state's healthcare sector. Both statutes take effect January 1, 2026, providing a nine-week implementation window for affected parties.
AB 1415 fundamentally expands the transactional authority of California's Office of Health Care Affordability. The law broadens OHCA's existing notice and review requirements to encompass private equity groups, hedge funds, management services organizations, and any entity that owns, operates, or controls a healthcare provider—regardless of current operational status. This expansion requires healthcare industry stakeholders and their advisors to file notification of transactions involving ownership or control changes, mergers, acquisitions, and MSO arrangements, subjecting these deals to OHCA's review process. Critically, OHCA now possesses explicit authority to collect data from these financial entities and analyze their role in healthcare costs, quality, access, and competitive dynamics. This data collection mandate creates an unprecedented transparency requirement for alternative investors in the healthcare space.
Senate Bill 351 addresses clinical autonomy and enforcement. The statute restricts private equity groups and hedge funds from interfering with independent clinical decision-making by physicians and dentists. While the law largely codifies existing judicial precedents and enforcement principles already developed through case law, it provides an explicit statutory mechanism authorizing California's attorney general to pursue enforcement actions against violators. This explicit authorization strengthens the state's legal arsenal and reduces reliance on common law theories in prosecuting alleged interference with medical practice.
Together, these laws reflect California's multi-year policy effort to constrain financial entity influence in healthcare markets. Healthcare deal participants must now anticipate extended regulatory review timelines, comprehensive data disclosure requirements, and heightened scrutiny of transaction structures involving alternative investors. The legislation establishes California as the leading state in healthcare transaction oversight, with implications for private equity and hedge fund portfolio management strategies across the industry.
AB 1415 fundamentally expands the transactional authority of California's Office of Health Care Affordability. The law broadens OHCA's existing notice and review requirements to encompass private equity groups, hedge funds, management services organizations, and any entity that owns, operates, or controls a healthcare provider—regardless of current operational status. This expansion requires healthcare industry stakeholders and their advisors to file notification of transactions involving ownership or control changes, mergers, acquisitions, and MSO arrangements, subjecting these deals to OHCA's review process. Critically, OHCA now possesses explicit authority to collect data from these financial entities and analyze their role in healthcare costs, quality, access, and competitive dynamics. This data collection mandate creates an unprecedented transparency requirement for alternative investors in the healthcare space.
Senate Bill 351 addresses clinical autonomy and enforcement. The statute restricts private equity groups and hedge funds from interfering with independent clinical decision-making by physicians and dentists. While the law largely codifies existing judicial precedents and enforcement principles already developed through case law, it provides an explicit statutory mechanism authorizing California's attorney general to pursue enforcement actions against violators. This explicit authorization strengthens the state's legal arsenal and reduces reliance on common law theories in prosecuting alleged interference with medical practice.
Together, these laws reflect California's multi-year policy effort to constrain financial entity influence in healthcare markets. Healthcare deal participants must now anticipate extended regulatory review timelines, comprehensive data disclosure requirements, and heightened scrutiny of transaction structures involving alternative investors. The legislation establishes California as the leading state in healthcare transaction oversight, with implications for private equity and hedge fund portfolio management strategies across the industry.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.